Sign in
Taking people in United StatesPhase 2

High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients

Key facts

Who runs it
National Institute of Allergy and Infectious Diseases (NIAID)
Where
Atlanta, Chicago, Cincinnati, Houston, Indianapolis, Kansas City, Nashville, Philadelphia, Pittsburgh, Seattle, and Stanford, United StatesSee the 11 sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
312 people, planned
Started
26 Sept 2024
Expected to end
1 Sept 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Standard Dose Quadrivalent Inactivated Influenza Vaccine
  • High Dose Quadrivalent Inactivated Influenza Vaccine
Record updated
28 October 2026

Who can take part

Age
3 years to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Male or female, 3-17 years of age at time of enrollment
  • Pediatric kidney, heart, and/or liver transplant recipient ≥1 month and <24 months post-transplant at the time of study immunization; Note: Inclusion of recipients of multiple organs is permitted but is limited to recipients of any combination of organs including kidney, heart and/or liver; Note: Participants undergoing re-transplantation are permitted
  • Anticipated to be available for duration of the study
  • Available by telephone, email, or text message

Who cannot take part

  • Receipt of current season's influenza vaccine post-transplant prior to enrollment in the study
  • Currently pregnant or lactating (females of childbearing age may be enrolled based on self-report, urine pregnancy test must be performed prior to each influenza vaccine)
  • History of severe hypersensitivity to influenza vaccination or anaphylaxis to eggs/egg protein
  • History of severe latex hypersensitivity
  • History of Guillain-Barre syndrome
  • History of lung or intestine transplant
  • HIV positive patients (testing within 24 months of enrollment)
  • Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
  • Inability (i.e. not able to understand and provide consent) or unwillingness of a participant/parent/legal guardian to give written informed consent or comply with study protocol

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 3 and 17 years old?

Where in United States

  • Children's Healthcare of AtlantaAtlanta, United StatesContact: ALEXANDRIA DRYERTaking people
  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesContact: Molly SchniedersTaking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: KERRIGAN PERKINSTaking people
  • Texas Children's HospitalHouston, United StatesContact: Christopher WilliamsTaking people
  • Indiana University School of Medicine, Riley Hospital for ChildrenIndianapolis, United StatesContact: Kirsten RyanTaking people
  • Children's Mercy HospitalKansas City, United StatesContact: MANDY MORGANTaking people
  • Monroe Carell Jr. Children's Hospital at VanderbiltNashville, United StatesContact: Haya Hayek, MBBSTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Morgan CrowleyTaking people
  • UPMC Children's Hospital of PittsburghPittsburgh, United StatesContact: ISAAC CASONTaking people
  • Seattle Children'sSeattle, United StatesContact: Zoe MunseyTaking people
  • Stanford UniversityStanford, United StatesContact: Hanqui SongTaking people

About the trial

What the trial wants to find out

Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses in SOT recipients: (1) administration of high-dose (HD)-IIV compared to SD-IIV and (2) two doses of SD-IIV compared to one dose of SD-IIV in the same influenza season. One study compared HD-IIV vs. SD-IIV in adult SOT recipients and noted that HD-IIV was safe and more immunogenic; however, the median post-transplant period was 38 months. A phase I pediatric study comparing a single dose of HD-IIV vs. SD-IIV was safe with higher immunogenicity, but the study was limited by small sample size and median post-transplant vaccine administration was 26 months. In another phase II trial of adult SOT recipients, two doses of SD-IIV one month apart compared to one-dose of SD-IIV revealed modestly increased immunogenicity when given at a median of 18 months post-transplant. Therefore, these studies lack both evaluation in the early post-transplant period and substantive pediatric populations. Additionally, the administration of two-doses of HD-IIV in the same influenza season has not been evaluated in pediatric SOT recipients. Thus, the optimal immunization strategy for pediatric SOT recipients less than 24 months post-transplant is unknown. In addition, immunologic predictors and correlates of influenza vaccine immunogenicity in pediatric SOT recipients have not been well-defined.

Read full original descriptionShow less

The central hypothesis of our proposal is that pediatric SOT recipients 1-23 months post-transplant who receive two doses of HD-quadrivalent inactivated influenza vaccine (QIV) will have similar safety but higher Hemagglutination Inhibition (HAI) geometric mean titers (GMTs) to influenza antigens compared to pediatric SOT recipients receiving two doses of SD-QIV.

The 2 groups in the trial

  • Two Doses Standard Dose Quadrivalent Inactivated Influenza VaccineTreatment being tested

    Two doses of SD-QIV (0.5 mL; 15µg of each influenza antigen) 28-42 days apart

    Treatment: Standard Dose Quadrivalent Inactivated Influenza Vaccine

  • Two Doses High Dose Quadrivalent Inactivated Influenza VaccineTreatment being tested

    Two doses of HD-QIV (0.7 mL; 60µg of each influenza antigen) 28-42 days apart

    Treatment: High Dose Quadrivalent Inactivated Influenza Vaccine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of High vs Standard Dose Influenza Vaccines in Pediatric Solid Organ Transplant Recipients
Fit questions
Built from NCT05947071, who can take part
Record updated
28 October 2026